LILAC Study
Back to ResearchFull Title: A Phase 3, multicenter, randomized, double‐blind, placebo-controlled, parallel‐group study to evaLuate the effIcacy and safety of abeLacimab in high‐risk patients with Atrial fibrillation who have been deemed unsuitable for oral antiCoagulation (LILAC)
The HCL research team is now participating in this study, which investigates the use of abelacimab for stroke prevention in patients with atrial fibrillation who can’t have DOACs either through choice or increased bleed risk (eg, frailty, renal impairment, previous GI bleeds, on antiplatelets, high HAS-BLED score).
Abelacimab is a monoclonal antibody which targets factor XI and so reduces stroke risk without a substantial increase in bleed risk. In the AZALEA–TIMI71 study, abelacimab was shown to be associated with only one-third of the bleeding rate compared to rivaroxaban.
We are looking for participants who may be able to benefit from a trial of this revolutionary new medication and need your help identifying them.
We are looking for patients with:-
- A diagnosis of atrial fibrillation
- and 65 years or older
- and not on a DOAC (either by patient choice or clinically high risk for a blood eg frailty, renal impairment, previous GI bleeds, taking antiplatelets, high HAS-BLED score)
If you have any patients which meet this criteria or have any queries, please email us at hcl.trials@nhs.net
